Name：LIU Rui

Department：Department of Organic Chemistry

Tel: (8610)67087731 (Tel/Fax)

Email: liurui@imb.pumc.edu.cn

Education & Research Experience

09/2006-07/2009, Ph.D. candidate, Pharmacology, Institute of Materia Medica, Peking Union Medical College

08/2009-09/2012, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Research Assistant

09/2012-11/2017, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Associate Professor, Master’s Supervisor

09/2014-09/2015, Xinjiang Institute of Materia Medica (Technical aid to Xinjiang), Associate Investigator, Associate Director of Pharmacology Department, Master’s Supervisor

01/2016-02/2018, Development Center for Medical Science and Technology, National Health and Family Planning Commission of the People’s Republic of China (On loan), Project Management Specialist, Associate Professor, Master’s Supervisor

11/2017-09/2018, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Associate Professor, Master’s Supervisor

09/2018 to now, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Professor, Master’s Supervisor, Doctoral Supervisor

Research Field：

Mechanism research, drug discovery, and drug effect related to neurodegenerative disorders, cerebrovascular diseases, and inflammatory-immune diseases.

Research Interests：

Main research area and subareas:

i) Genetic pathological mechanism in neurodegenerative disorders, involving non-coding genes, other epigenetic elements, and their target signaling transduction in the pathological process.

ii) Drug discovery methods, strategy, and compound screening and evaluation.

iii) Molecular pharmacological research of Traditional Chinese Medicines.

Additional research areas and subareas:

i) Oncology pharmacology and drug discovery, involving screening and evaluation of antitumor drug candidates, especially antibody-drug conjugate (ADC) compounds, and the mechanisms of effective anti-tumor compounds.

ii) Cardiovascular pharmacology and drug discovery, especially the druggability evaluation of drug candidate for cardiovascular protection.

Selected Publications

1. Hu X^#, Jiang H^#, Bai W, Liu X, Miao Q, Wang L, Jin J, Cui A, Liu R*, Li Z*. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates [J]. Eur J Med Chem. 2021; DOI: 10.1016/j.ejmech.2021.113297.

2. Zeng L, Jiang HL, Ashraf GM, Li ZR*, Liu R*. MicroRNA and messenger RNA profiling of cerebral cortex in a transgenic mouse model of Alzheimer’s disease by RNA sequencing [J]. Neural Regen Res. 2021;16(10):2099-2108.

3. Jiang H†, Zeng L†, Dong X, Guo S, Xing J, Li Z*, Liu R*. Tilianin Extracted From Dracocephalum moldavica L. Induces Intrinsic Apoptosis and Drives Inflammatory Microenvironment Response on Pharyngeal Squamous Carcinoma Cells via Regulating TLR4 Signaling Pathways [J]. Front Pharmacol. 2020;11:205.

4. Tencheva A†, Liu R†, Volkova TV, Chayrov R, Mitrev Y, Štícha M, Li Y, Jiang H, Li Z, Stankova I*, Perlovich GL*. Synthetic analogues of memantine as neuroprotective and influenza viral inhibitors: in vitro and physicochemical studies [J]. Amino Acids. 2020;52(11-12):1559-1580.

5. Wang L†, Liu J†, Wang Q, Jiang H, Zeng L, Li Z*, Liu R*. MicroRNA-200a-3p mediates neuroprotection in Alzheimer-related deficits and attenuates amyloid-beta overproduction and tau hyperphosphorylation via coregulating BACE1 and PRKACB [J]. Front Pharmacol. 2019;10:806.

6. Yuan F^#, Liu R^#, Hu M, Rong X, Bai L, Xu L, Mao Y, Hamulati H, Sun Y*, He J*. JAX2, an ethanol extract of Hyssopus cuspidatus Boriss, can prevent bronchial asthma by inhibiting MAPK/NF-κB inflammatory signaling [J]. Phytomedicine. 2019;57:305-314.

7. Liu QS, Deng R, Fan Y, Li K, Meng F, Li X*, Liu R*. Low dose of caffeine enhances the efficacy of antidepressants in major depressive disorder and the underlying neural substrates [J]. Mol Nutr Food Res. 2017;61(8):1600910.

8. LIU Rui; LI Zhuorong; JIANG Hailun; ZENG Li; ZHANG Junxia; miRNA MARKER FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER’S DISEASE: Australia, 2020103707[P].

9. LIU Rui; LI Zhuorong; ZENG Li; JIANG Hailun; ZHANG Junxia. USE OF miRNA30a CLUSTER AS DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR ALZHEIMER'S DISEASE: Australia, 2020103933[P].

10. Liu, Rui; Li, Zhuorong; Jiang, Hailun; Zeng, Li; Wang, Linlin；Use of miRNA 148 cluster as Marker for Diagnosing and/or Treating Cognitive Impairment-Associated Diseases: Australia, 2021101144[P].

Awards and Honors

i) New-Star Plan Award of Beijing Science and Technology (07/2013)

ii) Excellent Talent Award of Beijing Organization Department (11/2013)

iii) Third Prize of Beijing Science and Technology Award (01/2014)

iv) Young Science & Technology Award of Chinese Academy of Medical Sciences (01/2015)

v) First Prize of Beijing Youth Outstanding Scientific and Technological Paper (12/2015)

vi) Young Medical Talents Award Project of Chinese Academy of Medical Sciences (10/2018)

vii) First Prize of Excellent Thesis of National Academic Conference on Medicine Modernization and Clinics (12/2019)

viii) First Prize of Multimedia Educational Software in Ethnomedicine (11/2020)

ix) First Prize of Excellent Network Teaching in Pharmacology (01/2021)

Academic Appointments

i) Academic Editor of BioMed Research International (07/2013)

ii) Youth Member of Cerebrovascular Specialized Committee of Beijing Pharmacology Society (01/2015)

iii) Vice Secretary General of Professional Committee of Modernization and Clinics of Ethnomedicine, China Association of National Medicine (12/2018)

iv) Member of Committee of Anti-aging, China Association of Gerontology and Geriatrics (09/2019)

v) Youth Editor of Chinese Herbal Medicines (10/2019)

vi) Associate Editor of Journal of Alzheimers Disease (01/2020)